title: Regarding Waldinger and Schweitzer's "premature ejaculation and pharmaceutical company-based medicine: the dapoxetine case".
authors: Irwin
authors: I
authors: Goldstein
mesh_terms: D000818:Animals; D001596:Benzylamines / Q000627:therapeutic use*; D004353:Drug Evaluation, Preclinical; D004345:Drug Industry; D004542:Ejaculation / Q000187:drug effects; D019317:Evidence-Based Medicine; D006801:Humans; D008297:Male; D009281:Naphthalenes / Q000627:therapeutic use*; D009937:Organizational Objectives; D017367:Selective Serotonin Reuptake Inhibitors / Q000627:therapeutic use*; D012735:Sexual Dysfunction, Physiological / Q000188:drug therapy*
chemical_list: D001596:Benzylamines; D009281:Naphthalenes; D017367:Selective Serotonin Reuptake Inhibitors; C080598:dapoxetine